Sequana Medical Investor Presentation 2021

Sequana Medical presented its technology platform for treating diuretic-resistant fluid overload in liver disease, malignant ascites, and heart failure. The presentation covers the alfapump® system, which was under clinical investigation in the POSEIDON Study, and DSR® therapy in development. The company is addressing significant unmet medical needs in fluid management across multiple therapeutic areas.